Touyun Biotech (01332) has announced its financial results for the interim period of 2026, reporting a gross profit of HK$9.116 million, which represents a contraction of 32.71% compared to the same period last year.
The company recorded a profit attributable to owners of approximately HK$198 million, marking a substantial year-on-year increase of about 16.6 times. Earnings per share stood at 7.05 HK cents.
According to the company's announcement, the significant growth in profit was primarily driven by an increase in fair value gains on financial assets measured at fair value through profit or loss.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.